Four-year results of a phase 2 study of the cathepsin K inhibitor odanacatib in postmenopausal women with low bone mineral density: Effects on bone mineral density and bone turnover markers

Bone ◽  
2011 ◽  
Vol 48 ◽  
pp. S92
Author(s):  
H. Resch ◽  
N. Binkley ◽  
H. Bone ◽  
J. Eisman ◽  
D. Hosking ◽  
...  

Bone ◽  
2010 ◽  
Vol 47 ◽  
pp. S70-S71 ◽  
Author(s):  
H. Yamada⁎ ◽  
H. Mori ◽  
A. Kunishige ◽  
S. Nishikawa ◽  
Y. Hashimoto ◽  
...  


2014 ◽  
Vol 54 (8) ◽  
pp. 937-948 ◽  
Author(s):  
Chihiro Hasegawa ◽  
Helen Kastrissios ◽  
Jonathan Monteleone ◽  
Tomoya Ohno ◽  
Takeo Umemura ◽  
...  


2017 ◽  
Author(s):  
Agnieszka Rusinska ◽  
Izabela Michalus ◽  
Izabela Woch ◽  
Paulina Adamiecka ◽  
Danuta Chlebna-Sokol


2014 ◽  
Author(s):  
Mingo Dominguez Maria Luisa de ◽  
Sonsoles Guadalix Iglesias ◽  
Maria Begona Lopez Alvarez ◽  
Guillermo Martinez Diaz-Guerra ◽  
Federico Hawkins Carranza


2019 ◽  
Vol 17 (4) ◽  
pp. 102-106
Author(s):  
M. Yu. Smetanin ◽  
◽  
S. Yu. Nurgalieva ◽  
N. Yu. Kononova ◽  
L. T. Pimenov ◽  
...  


Bone ◽  
2006 ◽  
Vol 39 (5) ◽  
pp. 1136-1143 ◽  
Author(s):  
Hussein F. Saadi ◽  
Nicolaas Nagelkerke ◽  
Sheela Benedict ◽  
Hussein S. Qazaq ◽  
Erica Zilahi ◽  
...  




2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
A. Sánchez ◽  
L. R. Brun ◽  
H. Salerni ◽  
P. R. Costanzo ◽  
D. González ◽  
...  

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.





Sign in / Sign up

Export Citation Format

Share Document